We are live on ! Find out more
AGIO icon

Agios Pharmaceuticals
AGIO

215 hedge funds and large institutions have $2.05B invested in Agios Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 87 increasing their positions, 77 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

30% more call options, than puts

Call options by funds: $11.2M | Put options by funds: $8.65M

16% more capital invested

Capital invested by funds: $1.76B → $2.05B (+$289M)

13% more repeat investments, than reductions

Existing positions increased: 87 | Existing positions reduced: 77

1.63% more ownership

Funds ownership: 104.89% → 106.52% (+1.6%)

3% less funds holding

Funds holding: 221 → 215 (-6)

16% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 25

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

Holders
215
Holders Change
-6
Holders Change %
-2.71%
% of All Funds
2.83%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
21
Increased
87
Reduced
77
Closed
25
Calls
$11.2M
Puts
$8.65M
Net Calls
+$2.57M
Net Calls Change
+$3.05M

Top Buyers

Rank Fund Capital Flow
1
PBA
Paradigm Biocapital Advisors
New York
+$34.6M
2
TCM
TCG Crossover Management
California
+$21.1M
3
RSCM
Rock Springs Capital Management
Maryland
+$19.6M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$12.1M
5
CP
Caligan Partners
New York
+$11.2M

Top Sellers

Rank Fund Capital Flow
1
PCH
Polar Capital Holdings
United Kingdom
-$29.4M
2
AC
Armistice Capital
New York
-$26.7M
3
State Street
State Street
Massachusetts
-$15.1M
4
BlackRock
BlackRock
New York
-$8.33M
5
ACH
ArrowMark Colorado Holdings
Colorado
-$5.12M
Name Holding Trade Value Shares
Change 		Change in
Stake
Barclays
51
Barclays
United Kingdom
$6.01M +$2.05M +67,551 +60%
TD Asset Management
52
TD Asset Management
Ontario, Canada
$5.59M -$299K -9,878 -6%
Prudential Financial
53
Prudential Financial
New Jersey
$5.27M -$1.39M -45,883 -22%
PSC
54
Patient Square Capital
California
$4.65M – – –
Allianz Asset Management
55
Allianz Asset Management
Germany
$4.62M +$1.41M +46,665 +51%
CF
56
Cantor Fitzgerald
New York
$4.46M +$3.1M +102,200 +319%
Manulife (Manufacturers Life Insurance)
57
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$4.39M +$15.5K +512 +0.4%
Hudson Bay Capital Management
58
Hudson Bay Capital Management
Connecticut
$4.32M +$584K +19,280 +17%
American Century Companies
59
American Century Companies
Missouri
$4.25M +$385K +12,700 +11%
N
60
Nuveen
North Carolina
$3.98M +$1.1M +36,171 +43%
UBS Group
61
UBS Group
Switzerland
$3.95M -$388K -12,808 -10%
Invesco
62
Invesco
Georgia
$3.75M +$159K +5,250 +5%
Swiss National Bank
63
Swiss National Bank
Switzerland
$3.64M +$303K +10,000 +10%
CC
64
Casdin Capital
New York
$3.33M -$4.55M -150,000 -60%
TI
65
Trexquant Investment
Connecticut
$3.27M +$2.98M +98,401 New
AQR Capital Management
66
AQR Capital Management
Connecticut
$3.21M +$1.38M +45,407 +88%
RhumbLine Advisers
67
RhumbLine Advisers
Massachusetts
$2.99M +$92.1K +3,039 +3%
AG
68
Algert Global
California
$2.95M +$425K +14,020 +19%
SAM
69
Silvercrest Asset Management
New York
$2.75M – – –
MCM
70
Moore Capital Management
New York
$2.66M +$606K +20,000 +33%
HS
71
HighVista Strategies
Massachusetts
$2.33M +$789K +26,022 +59%
Capital Fund Management (CFM)
72
Capital Fund Management (CFM)
France
$2.28M -$115K -3,800 -5%
Susquehanna International Group
73
Susquehanna International Group
Pennsylvania
$2.27M -$420K -13,859 -17%
Qube Research & Technologies (QRT)
74
Qube Research & Technologies (QRT)
United Kingdom
$2.24M -$1.84M -60,601 -47%
Legal & General Group
75
Legal & General Group
United Kingdom
$2.14M +$129K +4,262 +7%
1 2
3
4 5

AGIO Hedge Fund Activity: Q2 2025 in Review

215 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Agios Pharmaceuticals (AGIO) for Q2 2025, worth a combined $2.05B — up 16% from $1.76B a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of AGIO and 21 opened new positions — a net loss of 4 holders — while 77 trimmed existing stakes and 87 added.

The largest buyer was Paradigm Biocapital Advisors, opening a new position worth an estimated $34.6M. The largest seller was Polar Capital Holdings, exiting entirely with an estimated $29.4M sold.

  • 215 institutional investors held Agios Pharmaceuticals (AGIO) as of Q2 2025, down from 221 in Q1 2025.
  • Funds reported $2.05B of Agios Pharmaceuticals stock for Q2 2025, up 16% quarter-over-quarter.
  • 21 funds opened new Agios Pharmaceuticals positions in Q2 2025 and 25 closed out, a net change of -4 holders.
  • The largest Agios Pharmaceuticals buyer in Q2 2025 was Paradigm Biocapital Advisors, an estimated $34.6M added.
  • The largest Agios Pharmaceuticals seller in Q2 2025 was Polar Capital Holdings, an estimated $29.4M sold.

Based on aggregated 13F filings for Q2 2025.